Advanced in Allergic Conjunctivitis

Dr. Joseph Tauber

Ophthalmology
4400 Broadway St, Ste 202, 
Kansas City, MO 
 (1300.9 mi)
Accepting New Patients
Advanced in Allergic Conjunctivitis
4400 Broadway St, Ste 202, 
Kansas City, MO 
 (1300.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Joseph Tauber is an Ophthalmologist in Kansas City, Missouri. Dr. Tauber and is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Dry Eye Syndrome, Conjunctivitis (Pink Eye), Interstitial Keratitis, and Episcleritis. Dr. Tauber is currently accepting new patients.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Allergic Conjunctivitis.

Specialties
Ophthalmology
Licenses
Ophthalmology in KS
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Aetna
  •  Humana

Locations

4400 Broadway St, Ste 202, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: February 16, 2023
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Enrollment Status: Completed
Publish Date: August 29, 2019
Intervention Type: Drug
Study Phase: Phase 1
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Enrollment Status: Terminated
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

28 Total Publications

Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials.
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials.
Journal: Frontiers in ophthalmology
Published: June 20, 2024
Similar Doctors
Advanced in Allergic Conjunctivitis
Dr. Steven M. Silverstein
Ophthalmology
Advanced in Allergic Conjunctivitis
Dr. Steven M. Silverstein
Ophthalmology

Silverstein Eye Centers PC

4240 Blue Ridge Blvd, Suite 1000, 
Kansas City, MO 
 (8.1 mi)
816-358-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Silverstein is an Ophthalmologist in Kansas City, Missouri. Dr. Silverstein and is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Conjunctivitis (Pink Eye), Cataract, Giant Papillary Conjunctivitis, Dry Eye Syndrome, and Cataract Removal. Dr. Silverstein is currently accepting new patients.

Advanced in Allergic Conjunctivitis
Dr. Timothy A. Walline
Ophthalmology
Advanced in Allergic Conjunctivitis
Dr. Timothy A. Walline
Ophthalmology

Sabates Eye Centers LLC

4320 Wornall Rd, Suite 220, 
Kansas City, MO 
 (0.1 mi)
913-261-2020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Walline is an Ophthalmologist in Kansas City, Missouri. Dr. Walline and is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Cataract, Conjunctivitis (Pink Eye), Allergic Conjunctivitis, and Dry Eye Syndrome. Dr. Walline is currently accepting new patients.

Advanced in Allergic Conjunctivitis
Dr. Anne B. Wishna
Ophthalmology
Advanced in Allergic Conjunctivitis
Dr. Anne B. Wishna
Ophthalmology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.3 mi)
913-588-6728
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Anne Wishna is an Ophthalmologist in Kansas City, Kansas. Dr. Wishna and is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. Her top areas of expertise are Meibomianitis, Dry Eye Syndrome, Cataract, and Sjogren Syndrome. Dr. Wishna is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile